Amedisys

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amedisys reports robust Q4 earnings, eyes growth amidst operational challenges

Amedisys showcases strong financial performance and strategic initiatives for 2023, focusing on growth and operational optimization.
Despite challenges like labor market issues and operational hurdles, the company remains confident in its growth strategies and talent management.
Opportunities in negotiations with payers, talent acquisition, and operational enhancements position Amedisys for continued success and revenue growth.
With a positive outlook for 2023 and a resilient approach to challenges, Amedisys is poised for steady growth and operational improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.

Align Technology

Jazz Pharmaceuticals

LHC Group

Mastercard

Moody's

Veeva Systems

The prospects of growth stocks appear bright for 2020, making the following companies attractive bets.

7 Impressive Growth Stocks to Buy for 2020

DaVita

Hanger Inc

Rosy Outlook for Outpatient and Home Healthcare Industry

Select Medical Holdings

Increasing incidence of chronic diseases, aging U.S. population, innovation and consolidation will drive the healthcare industry's growth in 2020.

5 Healthcare Stocks to Keep the Winning Streak Alive in 2020

Amedisys' (AMED) impressive performance in the newly-unveiled Personal Care segment is appreciative.

Amedisys (AMED) Benefits From Home Health and Personal Care

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?

Amedisys (AMED) Up 24.8% Since Last Earnings Report: Can It Continue?

Asana's acquisition to be the third hospice care buyout of Amedisys (AMED) in 2019.

Amedisys (AMED) to Broaden Hospice Base With Asana Purchase

PC Connection

NRG Energy

Target

Richard Herman Driehaus used the "buy high and sell higher" rule to create an investment approach, which appeals to those having a high level of risk appetite.

4 Momentum Picks  Screened on Driehaus Strategy

BATON ROUGE, La., Nov.  25, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal care company, has signed a definitive agreement to acquire Asana Hospice.

Amedisys to Acquire Asana Hospice

Tenet Healthcare

Prominent activities in the healthcare sector are pushing the sector ahead this quarter.

4 Healthcare Stocks to Gain From Stellar Q3 Earnings

Garmin

Ultra Clean

Top Ranked Momentum Stocks to Buy for November 22nd

Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Amedisys (AMED)

Bull of the Day: Amedisys (AMED)

Amedisys (AMED) aims to enhance clinician workflow by integrating nVoq's technology platform into its home health business.

Amedisys Partners With nVoq to Improve Clinician Experience

BATON ROUGE, La., Nov.  13, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the 2019 Jefferies London Healthcare Conference in London, England on Wednesday, November 20, 2019.

Amedisys to Present at the 2019 Jefferies London Healthcare Conference

Third Largest Hospice Provider Cared for 5,540 Dying Veterans Last Year Third Largest Hospice Provider Cared for 5,540 Dying Veterans Last Year

Amedisys Expanding Commitment to End-of-Life Care for Veterans

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Amedisys (AMED).

Is Amedisys (AMED) a Great Growth Stock?

TopBuild

HCA Healthcare

Lithia Motors

Pampa Energia

Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.

5 Stocks That Stand Out on Attractive Interest Coverage Ratio

BATON ROUGE, La., Nov.  05, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading independent home health, hospice and personal care company, is pleased to learn that the Centers for Medicare and Medicaid Services (CMS) has chosen to not finalize the entirety of the behavioral assumptions in the CY 2020 Home Health Final Rule and instead only apply 4.36%. This is welcome and warranted relief to patients and the home health industry. If the behavioral assumption reduction of 8% had been fully implemented in the first year of PDGM, patient access would have been significantly impacted as it was projected that as much as a third of the home health industry, especially in rural areas, would have been at risk.

Media Statement from Amedisys Regarding CY 2020 Home Health Final Rule

Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Amedisys (AMED) Soars to 52-Week High, Time to Cash Out?

Amedisys (AMED) continues to witness solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.

Amedisys (AMED) Q3 Earnings Beat Estimates, Revenues Meet

Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.

Is Amedisys (AMED) a Solid Growth Stock? 3 Reasons to Think " Yes "

Addus HomeCare

Bluerock Residential Growth REIT

AquaVenture Holdings

Fed was compelled to reduce it in three consecutive and equal tranches of 25 basis points to sustain the expansion of the U.S. economy.

5 Top Stocks to Gain From Fed's Stable Monetary Stance

Amedisys, Inc. (AMED) CEO Paul Kusserow on Q3 2019 Results - Earnings Call Transcript

Hint: Adjusted earnings numbers can involve plenty of adjustments.

How Amedisys Blew Past Q3 Earnings Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 27.78% and 0.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) Beats Q3 Earnings and Revenue Estimates

News for Amedisys Stock (AMED)